Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kris Poulsen is active.

Publication


Featured researches published by Kris Poulsen.


Neuron | 1998

Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin

Jeffrey Milbrandt; Frederic J. de Sauvage; Timothy J. Fahrner; Robert H. Baloh; Melanie L. Leitner; Malú G. Tansey; Patricia A. Lampe; Robert O. Heuckeroth; Paul T. Kotzbauer; Kelli S. Simburger; Judith P. Golden; Jamie A. Davies; Richard Vejsada; Ann C. Kato; Mary Hynes; Daniel Sherman; Merry Nishimura; Li-Chong Wang; Richard Vandlen; Barbara Moffat; Robert D. Klein; Kris Poulsen; Christa L. Gray; Alain Garces; Christopher E. Henderson; Heidi S. Phillips; Eugene M. Johnson

A novel neurotrophic factor named Persephin that is approximately 40% identical to glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) has been identified using degenerate PCR. Persephin, like GDNF and NTN, promotes the survival of ventral midbrain dopaminergic neurons in culture and prevents their degeneration after 6-hydroxydopamine treatment in vivo. Persephin also supports the survival of motor neurons in culture and in vivo after sciatic nerve axotomy and, like GDNF, promotes ureteric bud branching. However, in contrast to GDNF and NTN, persephin does not support any of the peripheral neurons that were examined. Fibroblasts transfected with Ret and one of the coreceptors GFRalpha-1 or GFRalpha-2 do not respond to persephin, suggesting that persephin utilizes additional, or different, receptor components than GDNF and NTN.


Nature | 1997

A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.

Robert D. Klein; Daniel Sherman; Wei-Hsien Ho; Donna M. Stone; Gregory L. Bennett; Barbara Moffat; Richard Vandlen; Laura Simmons; Qimin Gu; Jo-Anne Hongo; Brigitte Devaux; Kris Poulsen; Mark Armanini; Chika Nozaki; Naoya Asai; Audrey Goddard; Heidi S. Phillips; Chris E. Henderson; Masahide Takahashi; Arnon Rosenthal

Glial-cell-line-derived neurotrophic factor (GDNF) and neurturin (NTN) are two structurally related, potent survival factors for sympathetic, sensory and central nervous system neurons. GDNF mediates its actions through a multicomponent receptor system composed of a ligand-binding glycosyl-phosphatidylinositol (GPI)-linked protein (designated GDNFR-α) and the transmembrane protein tyrosine kinase Ret. In contrast, the mechanism by which the NTN signal is transmitted is not well understood. Here we describe the identification and tissue distribution of a GPI-linked protein (designated NTNR-α) that is structurally related to GDNFR-α. We further demonstrate that NTNR-α binds NTN (Kd ∼ 10 pM) but not GDNF with high affinity; that GDNFR-α binds to GDNF but not NTN with high affinity; and that cellular responses to NTN require the presence of NTNR-α. Finally, we show that NTN, in the presence of NTNR-α, induces tyrosine-phosphorylation of Ret, and that NTN, NTNR-α and Ret form a physical complex on the cell surface. These findings identify Ret and NTNR-α as signalling and ligand-binding components, respectively, of a receptor for NTN and define a novel family of receptors for neurotrophic and differentiation factors composed of a shared transmembrane protein tyrosine kinase and a ligand-specific GPI-linked protein.


Neuron | 1994

TGFβ2 and TGFβ3 are potent survival factors for midbrain dopaminergic neurons

Kris Poulsen; Mark Armanini; Robert D. Klein; Mary Hynes; Heidi S. Phillips; Arnon Rosenthal

The vertebrate ventral midbrain contains 3-4 x 10(4) dopaminergic neurons that influence motor activity, emotional behavior, and cognition. Recently, glial cell line-derived neurotrophic factor (GDNF) was shown to be a potent survival factor for these dopaminergic neurons in culture. However, many midbrain dopaminergic neurons project to targets that do not express GDNF. We report here that transforming growth factors (TGFs) TGF beta 2 and TGF beta 3, which are distantly related to GDNF, also prevent the death of cultured rat embryonic midbrain dopaminergic neurons at picomolar concentrations. Furthermore, we find that TGF beta 2, TGF beta 3, and GDNF are expressed sequentially as local and target-derived trophic factors and that subpopulations of dopaminergic neurons projecting to distinct targets have access to only one of these factors. These findings are consistent with the idea that GDNF, TGF beta 2, and TGF beta 3 are physiological survival factors for developing midbrain dopaminergic neurons and may have applications as therapeutics for Parkinsons disease, a neurodegenerative disorder of dopaminergic neurons.


Cell | 1995

Control of neuronal diversity by the floor plate: Contact-mediated induction of midbrain dopaminergic neurons

Mary Hynes; Kris Poulsen; Marc Tessier-Lavigne; Arnon Rosenthal

The notochord and floor plate contribute to patterning the ventral neural tube in part by expressing a diffusible factor that induces motoneurons. To determine the mechanisms that direct the development of other classes of ventral neurons, we studied the development of dopaminergic neurons that reside near motoneurons in the ventral midbrain. We provide evidence that dopaminergic neurons develop in the vicinity of the floor plate and that they can be specified by the floor plate in vitro and in vivo. Unlike motoneurons, efficient induction of dopaminergic neurons requires contact with floor plate cells. These results suggest that neuronal diversification along the dorsal-ventral axis may be achieved partly through the concerted action of diffusible and contact-dependent signals from a single organizing center, the floor plate.


Bioconjugate Chemistry | 2015

Effect of attachment site on stability of cleavable antibody drug conjugates.

Magdalena Grazyna Dorywalska; Pavel Strop; Jody A. Melton-Witt; Adela Hasa-Moreno; Santiago E. Farias; Meritxell Galindo Casas; Kathy Delaria; Victor Lui; Kris Poulsen; Carole M. Loo; Stellanie Krimm; Gary Louis Bolton; Ludivine Moine; Russell Dushin; Thomas-Toan Tran; Shu-Hui Liu; Mathias Rickert; Davide Foletti; David L. Shelton; Jaume Pons; Arvind Rajpal

The systemic stability of the antibody-drug linker is crucial for delivery of an intact antibody-drug conjugate (ADC) to target-expressing tumors. Linkers stable in circulation but readily processed in the target cell are necessary for both safety and potency of the delivered conjugate. Here, we report a range of stabilities for an auristatin-based payload site-specifically attached through a cleavable valine-citrulline-p-aminobenzylcarbamate (VC-PABC) linker across various sites on an antibody. We demonstrate that the conjugation site plays an important role in determining VC-PABC linker stability in mouse plasma, and that the stability of the linker positively correlates with ADC cytotoxic potency both in vitro and in vivo. Furthermore, we show that the VC-PABC cleavage in mouse plasma is not mediated by Cathepsin B, the protease thought to be primarily responsible for linker processing in the lysosomal degradation pathway. Although the VC-PABC cleavage is not detected in primate plasma in vitro, linker stabilization in the mouse is an essential prerequisite for designing successful efficacy and safety studies in rodents during preclinical stages of ADC programs. The divergence of linker metabolism in mouse plasma and its intracellular cleavage offers an opportunity for linker optimization in the circulation without compromising its efficient payload release in the target cell.


Nature Biotechnology | 2015

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

Pavel Strop; Kathy Delaria; Davide Foletti; Jody Melton Witt; Adela Hasa-Moreno; Kris Poulsen; Meritxell Galindo Casas; Magdalena Grazyna Dorywalska; Santiago E. Farias; Ariel Pios; Victor Lui; Russell Dushin; Dahui Zhou; Thayalan Navaratnam; Thomas-Toan Tran; Janette Sutton; Kevin Lindquist; Bora Han; Shu-Hui Liu; David L. Shelton; Jaume Pons; Arvind Rajpal

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading


Nature | 1998

Correction: A GPI-linked protein that interacts with Retto form a candidate neurturin receptor

Robert D. Klein; Daniel Sherman; Wei-Hsien Ho; Donna M. Stone; Gregory L. Bennett; Barbara Moffat; Richard Vandlen; Laura Simmons; Qimin Gu; Jo-Anne Hongo; Brigitte Devaux; Kris Poulsen; Mark P. Armanini; Chika Nozaki; Naoya Asai; Audrey Goddard; Heidi S. Phillips; Chris E. Henderson; Masahide Takahashi; Arnon Rosenthal

This corrects the article DOI: 10.1038/42722


Nature | 1996

Characterization of a multicomponent receptor for GDNF.

Treanor Jj; Goodman L; de Sauvage F; Donna M. Stone; Kris Poulsen; Beck Cd; Christine Gray; Mark Armanini; Ra Pollock; Franz Hefti; Heidi S. Phillips; Audrey Goddard; Mw Moore; Anna Buj-Bello; Alun M. Davies; Naoya Asai; Masahide Takahashi; Richard A. Vandlen; Chris E. Henderson; Arnon Rosenthal


Nature | 1995

Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

Klaus D. Beck; Janet Valverde; Tajrena Alexi; Kris Poulsen; Barbara Moffat; Richard A. Vandlen; Arnon Rosenthal; Franz Hefti


The Journal of Neuroscience | 1998

Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons

Brian A. Horger; Merry Nishimura; Mark Armanini; Li-Chong Wang; Kris Poulsen; Carl Rosenblad; Deniz Kirik; Barbara Moffat; Laura Simmons; Eugene M. Johnson; Jeff Milbrandt; Arnon Rosenthal; Anders Björklund; Richard A. Vandlen; Mary Hynes; Heidi S. Phillips

Collaboration


Dive into the Kris Poulsen's collaboration.

Researchain Logo
Decentralizing Knowledge